Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

NVO to Co-Develop Septerna’s Oral Therapies for Obesity/Diabetes. Novo Nordisk signed a licensing deal with Septerna to co ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...